Hoofddorp, the Netherlands, 30 August 2023. IGEA Pharma N.V. (SIX: IGPH) today announced the filing of the appeal to the decision of the SIX to delist the company.
Ad hoc announcement pursuant to article 53 LR
IGEA to update on SIX decision
Hoofddorp, the Netherlands, 4 August 2023. IGEA Pharma N.V. (SIX: IGPH) today announced the intention to appeal the decision of the SIX to delist the company.
IGEA discloses its Annual Report 2022
Hoofddorp, the Netherlands, 30 July 2023. IGEA Pharma N.V. (SIX: IGPH) announced the disclosure if its Annual Report 2022.
IGEA to apply for a further extension of its disclosure obligations
Hoofddorp, the Netherlands, 31 May 2023. IGEA Pharma N.V. (SIX: IGPH) today announced the
submission of a further exemption application to the SIX.
IGEA to update on strategic refocusing decisions.
Hoofddorp, the Netherlands, 30 May 2023. IGEA Pharma N.V. (SIX: IGPH) today announced a refocusing on its industrial process segment.
IGEA to update on unaudited key figures and ongoing matters
Hoofddorp, the Netherlands, 15 May 2023. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of unaudited key figures (as anticipated on 30 April 2023) and certain other ongoing matters as follow:
Minutes of the EGM of 24 April 2023 + Attendance list
Minutes of the Extraordinary General Meeting (the “Meeting”) of IGEA Pharma N.V., a public limited company (in Dutch: naamloze vennootschap), having its statutory seat in Amsterdam, the Netherlands, and its registered office address at Siriusdreef 17, 2132WT Hoofddorp, the Netherlands, registered with the Trade Register of the Dutch Chamber of Commerce under number: 70212821 (the “Company”), held physically at the Company’s office with address at Siriusdreef 17, 2131 WT Hoofddorp, the Netherlands on 24 April 2023 at 14:00 hours CET.
IGEA to get SIX approval to Annual 2022 Report disclosure
Hoofddorp, the Netherlands, 30 April 2023. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2022 Annual Report.
Convening notice & Agenda
Dear Shareholder,
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites you to attend the Extraordinary General Meeting on 24.04.2023 (the “EGM”) that will take place at the offices of the Company at Siriusdreef 17, 2123 WT Hoofddorp. The meeting will start at 14:00 hours CEST and is to be attended physically. Registration will start at 13:00 hours CEST.
IGEA appoints new Chief Financial Officer
Hoofddorp, the Netherlands, 08 December 2022. IGEA Pharma N.V. (SIX: IGPH) today appointed Diego Fiorentini as new CFO of IGEA Pharma, filling a void that was ad interim covered by the previous CEO.